Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario de Guadalajara (56)

2024

  1. Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice

    Medicina (Lithuania), Vol. 60, Núm. 1

  2. Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy

    Clinical and Translational Oncology

  3. Predictive and Prognostic 18F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223Ra

    Cancers, Vol. 16, Núm. 15

2023

  1. Emerging histological and serological biomarkers in oral squamous cell carcinoma: Applications in diagnosis, prognosis evaluation and personalized therapeutics (Review)

    Oncology reports, Vol. 50, Núm. 6

  2. Prevención de las complicaciones de las metástasis óseas por cáncer de prostate

    Revisiones en Cancer, Vol. 37, Núm. 6, pp. 284-292

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2021

  1. Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis

    Cancer Treatment Reviews, Vol. 93

2020

  1. Latest progress in molecular biology and treatment in genitourinary tumours

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195

2019

  1. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

  2. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

    Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789

2018

  1. Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG

    Clinical and Translational Oncology, Vol. 20, Núm. 3, pp. 392-401

  2. Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (57-68), 10.1007/s12094-017-1783-2)

    Clinical and Translational Oncology

  3. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 57-68

2017

  1. Anemia and Cancer: Proper use of hematopoietic factors

    Cancer and Chemotherapy Reviews, Vol. 12, Núm. 2, pp. 39-45

  2. Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido

    Enfermedades Infecciosas y Microbiologia Clinica

  3. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy

    Clinical and Translational Oncology, Vol. 19, Núm. 10, pp. 1175-1182

2016

  1. Management of infection and febrile neutropenia in patients with solid cancer

    Clinical and Translational Oncology, Vol. 18, Núm. 6, pp. 557-570

  2. Prevención de las complicaciones de las metástasis óseas por cáncer de próstata

    Revisiones en Cancer, Vol. 30, Núm. 1, pp. 35-44

  3. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

  4. Retrospective analysis of metastatic non-clear cell renal carcinoma (NCCRC): the Spanish Grupo Centro Experience

    Annals of Oncology, Vol. 27, pp. vi290